respiratory
Medicines

PBS funding recommended for dual combination therapy in PAH


The PBS has signalled a move to subsidise dual combination therapy for patients with pulmonary arterial hypertension (PAH). A recommendation to subsidise combination therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE-5) inhibitor for patients with WHO Functional Class III and...

The PBS has signalled a move to subsidise dual combination therapy for patients with pulmonary arterial hypertension (PAH). A recommendation to...

Read more